News and Trends 27 Apr 2021
EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing…
Actelion
- Latest Posts
In Depth 23 Dec 2020
Humble Beginnings: The Origin Story of Modern Biotechnology
The history of modern biotechnology began around four decades ago with the invention of genetic engineering. Genentech, one of the…
Best in Biotech 21 May 2019
The Top 20 Women in Leading Biotech Roles in Europe
The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way…
Best in Biotech 2 Apr 2019
The 8 Best Biotech Companies in Europe’s History
We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and…
ADVERTISEMENT
More News! 18 Jun 2018
Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage
Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries…
News and Trends 1 Mar 2018
How is Actelion Spin-Off Idorsia Doing One Year Later?
Actelion's spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year…
In Depth 23 Jan 2018
Walking with the Dinosaurs of European Biotech: Which of Them is Roaring the Loudest?
Although biotech may seem like an industry that has only just gotten started, it was already up and running before…
News and Trends 20 Dec 2017
Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies
Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license…
Best in Biotech 12 Dec 2017
Grab the Tissues: Here are the 8 Biggest European Biotech Clinical Failures of 2017
As 2016 was a tough year for biotech, 2017 was under pressure to turn things around. Although there has been…
Best in Biotech 5 Dec 2017
Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017
Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the…
ADVERTISEMENT
News and Trends 4 Dec 2017
Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III
Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart…
In Depth 25 Apr 2017
How Biotech is Mastering Multiple Sclerosis: A Review
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first,…
Best in Biotech 18 Apr 2017
The Top 12 Biotech Leaders You Should Know in Basel
After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people that should be on your…
Best in Biotech 15 Mar 2017
What are the Best Countries to Recruit Biotech Talents in 2017?
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look…
Infographics 21 Feb 2017
Infographic: The Biggest Biotech Company in Each European Country
We had a look into European biotech and created a map with the biggest biotech companies in each country, according…
News and Trends 15 Feb 2017
Actelion’s key Drug linked to Deaths, prompting EMA Investigation
Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion's…
ADVERTISEMENT
News and Trends 26 Jan 2017
Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B
Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into…
News and Trends 23 Jan 2017
A Placebo beats the Largest European Biotech in Phase III
Actelion's lead drug Opsumit has missed its primary endpoint in Phase III. What are the consequences for the biggest independent…
News and Trends 13 Jan 2017
UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out
UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26)…
In Depth 5 Jan 2017
What to Expect from European Biotech Finance in 2017
The new year comes with uncertainty over the future of the biotech industry, whose finance suffered during 2016. What are…